Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

PURPOSE: This international phase III trial (Investigating Torisel As Second-Line Therapy [INTORSECT]) compared the efficacy of temsirolimus (mammalian target of rapamycin inhibitor) and sorafenib (vascular endothelial growth factor receptor [VEGFR] tyrosine kinase inhibitor) as second-line therapy...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Hutson, Thomas E., Escudier, Bernard, Esteban, Emilio, Bjarnason, Georg A., Lim, Ho Yeong, Pittman, Kenneth B., Senico, Peggy, Niethammer, Andreas, Lu, Dongrui Ray, Hariharan, Subramanian, Motzer, Robert J.
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2014
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569683/
https://ncbi.nlm.nih.gov/pubmed/24297950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.50.3961
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires